Impact of HLA-B*35 subtype differences on HIV disease outcome in Mexico
Juarez-Molina CI., Valenzuela-Ponce H., Avila-Rios S., Garrido-Rodriguez D., Garcia-Tellez T., Soto-Nava M., Garcia-Morales C., Goulder P., Reyes-Teran G.
HLA-B*35 has consistently been associated with rapid HIV disease progression, particularly alleles of the Px group. As B*35 is the most prevalent HLA-B in Mexico, we investigated HIV disease outcome in relation to HLA expression in a large cohort (n=976) of Mexicans. Contrary to the previous studies, no impact on viral load or CD4+ cell count was observed in association with the B*35 PY/Px groups. However, we observed differences in HIV disease outcome associated with specific HLA-B*35 alleles. © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins.